GHRH analogue raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2026-03-19 and is reviewed periodically as new material appears.
Naming in this area is inconsistent, and readers should treat product labels with care. In much of the literature and in vendor catalogs, the unqualified term refers to the albumin-binding version, while the version lacking the DAC group appears as modified GRF(1-29), mod GRF(1-29), or the same name with a without-DAC qualifier. Because one abbreviation has been applied to both materials, the only reliable way to identify a sample is to check the stated sequence and the presence of the linker.
CJC-1295 is the name used for a synthetic peptide modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. The compound was described by a Canadian drug discovery company in the mid-2000s as a long-acting research tool. Two closely related molecules share the name in practice: one carries a drug affinity complex, or DAC, group, and one does not. The distinction matters because the two behave differently in circulation.
The peptide backbone corresponds to GRF(1-29), the first 29 residues of native growth hormone-releasing hormone, which retains most of the receptor-activating activity of the full-length molecule. Four substitutions distinguish the analog from the natural sequence: D-alanine at position 2, glutamine at position 8, alanine at position 15, and leucine at position 27. These changes slow cleavage by dipeptidyl peptidase IV, the enzyme that degrades native hormone in plasma within minutes. The outcome is improved enzymatic stability combined with a still brief residence time when no additional modification is present.
Reported half-lives differ widely between the two variants and between species. Values for the albumin-binding form are usually expressed in days, while the unconjugated form is measured in minutes to a few hours. Sampling schedules, assay sensitivity, and route of administration all influence the numbers, which limits direct comparison across studies. Whether sustained receptor occupancy produces different downstream effects from pulsatile stimulation remains an open question in the published work. Claims about relative potency should therefore be read alongside the specific study design that produced them.
Lyophilised powder is the usual supplied form. The material is hygroscopic, so vials are typically equilibrated to room temperature before opening in order to prevent condensation on the contents. Long-term storage is generally described at minus twenty degrees Celsius or colder, protected from light and moisture. Repeated freeze-thaw cycles are avoided because they promote aggregation and loss of soluble material. A reconstituted solution is considerably less stable than the dry powder and is normally kept refrigerated for short periods only.
Identity and purity are assessed mainly by reversed-phase high-performance liquid chromatography combined with mass spectrometry. The chromatographic separation resolves the target peptide from truncation products and from species carrying oxidised residues, while mass measurement confirms the expected molecular mass. Because the two common variants differ by roughly 280 daltons, a mass determination distinguishes them unambiguously. Purity is often quoted as a percentage of total peak area, although that figure depends on the detection wavelength and the integration method applied.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | GHRH analog, not a steroid |
| Backbone length | 29 amino acids | Based on GRF(1-29) |
| Substitutions | Four positions | D-Ala2, Gln8, Ala15, Leu27 |
| Appearance | White to off-white powder | Typical lyophilized research material |
| Common synonyms | Modified GRF(1-29) | Usage varies between sources |
Two forms circulate in research settings and are frequently confused. One carries the drug affinity complex and is often written as CJC-1295 with DAC; the other lacks that group and is usually called modified GRF(1-29). The two share the same core sequence but differ sharply in how long they persist in blood. Products labelled only as CJC-1295 normally refer to the version carrying the complex. Documentation that omits the distinction leaves the intended molecule ambiguous.
CJC-1295 is a synthetic peptide built as a long-acting analogue of growth hormone-releasing hormone. Its backbone matches the first twenty-nine residues of the natural human hormone, with four amino acid substitutions added to slow enzymatic breakdown. A reactive maleimide group, commonly termed the drug affinity complex, allows the peptide to attach to circulating albumin after administration. That albumin attachment keeps the molecule in the bloodstream for an extended period instead of being cleared within minutes.
The compound emerged from work at a Canadian biotechnology firm in the early 2000s. Early human studies examined its effect on growth hormone and insulin-like growth factor 1 in healthy volunteers and in people with HIV-associated fat redistribution. Reports described sustained increases in both markers after a single injection. Development did not advance to regulatory approval, and the clinical programme was later discontinued. The molecule is now encountered mainly as a research chemical rather than a marketed medicine.
Two related forms circulate in technical discussion under the same family name. The original version carries a drug affinity complex (DAC) that binds covalently to serum albumin after administration, and this linkage substantially extends circulation time. A second form, frequently written as modified GRF(1-29) or CJC-1295 without DAC, lacks that linker and clears much faster. The naming is a frequent source of confusion because the shorthand CJC-1295 can refer to either form depending on the source. Reports sometimes fail to specify which variant was studied.
The peptide backbone includes a D-alanine at position two, which resists cleavage by dipeptidyl peptidase IV, and several other substitutions that reduce degradation. Its molecular weight is roughly 3.4 kDa without the linker and about 3.6 kDa with it. The molecule is water soluble and is normally supplied as a lyophilized powder. Precise sequence and mass values depend on which variant is described, so technical documents usually state the exact form being referenced.
CJC-1295 is a synthetic peptide designed as a long-acting analogue of growth hormone-releasing hormone (GHRH). Its structure derives from the first 29 amino acids of native GHRH, a fragment often called GRF(1-29). Four substitutions were introduced to slow enzymatic breakdown and extend activity relative to the natural sequence. The compound was developed by ConjuChem as part of a broader effort to improve the pharmacokinetic profile of peptide hormones. It is studied in laboratory and clinical research settings rather than appearing as a naturally occurring substance.
Laboratory handling centers on minimizing exposure to water, heat and oxygen before use. Working solutions are typically prepared in sterile water or a mild buffer, and any residual particulate matter is removed by filtration. When the powder dissolves slowly, a small proportion of acetonitrile or dilute acetic acid is sometimes added as a co-solvent. Containers are kept sealed and desiccated between uses. Records of lot number, reconstitution date and storage conditions support later comparison of results across experiments.
Identity and purity are established with reversed phase high performance liquid chromatography coupled to mass spectrometry. The chromatographic step separates the target peptide from truncated sequences and deletion products, while the mass measurement confirms the expected molecular weight to within a fraction of a dalton. Because the two common variants differ by the presence of the linker, mass alone can distinguish them in the unconjugated state. Amino acid analysis and peptide mapping are used when sequence level confirmation is required.
Two forms circulate under the CJC-1295 name, and they differ by a single appended group. The version without a drug affinity complex carries four substitutions along the peptide chain, including a D-alanine near the amino terminus and replacements at three other positions. These changes block the enzyme dipeptidyl peptidase IV and remove a methionine residue that is prone to oxidation. The modified fragment is frequently labeled MOD GRF 1-29. Naming conventions are inconsistent across informal sources, which is a common source of confusion.
The second form adds a maleimide-bearing linker to the lysine at the carboxyl end. This group reacts with cysteine-34 on circulating serum albumin, forming a covalent bond that keeps the peptide in the bloodstream for far longer. ConjuChem developed the molecule as a way to extend the action of a peptide without frequent administration. The albumin attachment is the defining structural feature of the drug affinity complex version. Whether continuous exposure produces effects distinct from shorter pulses remains an unresolved research question.
In general, cells are cultivated in unlabeled or stable (non-radioactive) isotope labeled media. For example, the medium can contain glucose labeled with six carbon-13 atoms (13C) instead of the normal carbon-12 (12C). Cells growing in this medium, will, depending on model organism, incorporate the heavy glucose into all of their RNA molecules. Thereafter, all nucleotides are 5 Da heavier than their unlabeled isotopologues due to a complete carbon labeling of the ribose. After cultivation and appropriate labeling of the cells, they are generally harvested using phenol/chloroform/guanidinium isothiocyanate. Other extraction methods are possible and sometimes needed (e.g. for yeast). RNA is then isolated by Phenol-Chloroform extraction and iso-Propanol precipitation. Further purification of specific RNA species (e.g. rRNA, tRNA) is usually done by size-exclusion chromatography (SEC) but other approaches are available as well. For most applications the final product needs to be enzymatically digested to nucleosides before analysis by LC-MS. Therefore, digestion enzymes such as benzonase, NP1 and CIP are used. Typically, a triple quadrupole in MRM mode is used for the measurements.
=== 2011–2016: The Devil Put Dinosaurs Here === On March 21, 2011, Alice in Chains announced that they were working on a fifth studio album, and both Cantrell and Inez later made statements that they had begun the recording process. The album was expected to be finished by summer of 2012 and released by the end of 2012 or beginning of 2013. While Alice in Chains were writing for the album in 2011, Cantrell underwent surgery on his right shoulder, which delayed recording the new material. In an interview published in May 2012, Cantrell explained, "The thing that set me back is I had some bone spurs [and] cartilage issues in my shoulders. I had the same issue in the other shoulder about six years ago so I've had them both done now. It's a repetitive motion injury from playing." Cantrell could not play guitar for eight months while he was recovering from surgery. While recuperating at home in a sling, Cantrell heard a riff in his head and sang it into his phone. The riff later became the song "Stone". Alice in Chains played their first concert in nearly 10 months and their first concert after Cantrell's shoulder surgery at the Winstar Casino in Thackerville, Oklahoma on August 13, 2011. The band's only concert in 2012 was a five-song acoustic set on May 31 at the eighth annual MusiCares MAP Fund Benefit Concert honoring Jerry Cantrell.
== Causes == Colombia has a long history of political violence. Land, power, and wealth were unevenly distributed and many rural citizens were used to having to fend for themselves. There is no consensus about the date on which the conflict began, with some saying 1958 (with the start of the Frente Nacional (National Front)) and others 1964 (with the creation of the FARC). In the mid-1980s, Colombia granted local governments greater political and fiscal autonomy. This strengthened the government's position in more remote regions. In 1985, during peace talks with then-President Belisario Betancur, the FARC created the left-wing Patriotic Union party as a route from violence to mainstream politics. Between 1985 and 2002, 4,153 members and supporters of the party were kidnapped and murdered by right-wing paramilitaries with government support. This included two presidential candidates, 6 out of 16 congressmembers, 17 regional representatives, and 163 councilmembers. These killings aggravated the conflict. In the 1980s, drug trafficking increased, bringing a concomitant increase in violence. Trafficking began in the 1960s and 70s when a group of Americans began to smuggle marijuana. Later, the American Mafia moved into drug trafficking in Colombia alongside local marijuana producers. Cocaine and other drugs produced in Colombia were mostly consumed in the US, as well as Europe. Organized crime in Colombia grew increasingly powerful in the 1970s and 80s with the introduction of massive drug trafficking to the United States from Colombia.
Later in September Roche announced its intention to acquire Tusk Therapeutics for up to €655 million ($759 million) expanding Roche's oncology pipeline. Tusk announced that the anti-CD38 antibody it is developing will be spun off to form a new company, Black Belt Therapeutics. In late November, the company announced that Genentech would acquire Jecure Therapeutics, gaining access to Jecure's portfolio of NLRP3 inhibitors developed to fight inflammatory diseases like non-alcoholic steatohepatitis and liver fibrosis. In February 2019, the business announced it would acquire gene therapy company, Spark Therapeutics, for US$4.3 billion ($114.50 per share) adding Spark's gene therapy portfolio to its previous acquired assets. Spark has an already approved treatment for Leber's congenital amaurosis, Luxturna – priced at US$850,000 per patient. The offer to acquire Spark Therapeutics was extended to May 2019 after Roche was unable to garner majority support from Spark shareholders. A second gene therapy-related action came in December with the US$1.15 billion acquisition of non-United States rights to an investigational duchenne muscular dystrophy gene therapy developed by Sarepta Therapeutics. In November, Roche acquired Promedior and its lead treatment – PRM-151 – for the treatment of idiopathic pulmonary fibrosis, for $390 million upfront and another $1 billion in milestone payments.
== Detectors == A time-of-flight mass spectrometer (TOFMS) consists of a mass analyzer and a detector. An ion source (either pulsed or continuous) is used for lab-related TOF experiments, but not needed for TOF analyzers used in space, where the sun or planetary ionospheres provide the ions. The TOF mass analyzer can be a linear flight tube or a reflectron. The ion detector typically consists of microchannel plate detector or a fast secondary emission multiplier (SEM) where first converter plate (dynode) is flat. The electrical signal from the detector is recorded by means of a time to digital converter (TDC) or a fast analog-to-digital converter (ADC). TDC is mostly used in combination with orthogonal-acceleration (oa)TOF instruments. Time-to-digital converters register the arrival of a single ion at discrete time "bins"; a combination of threshold triggering and constant fraction discriminator (CFD) discriminates between electronic noise and ion arrival events. CFD converts nanosecond-long Gaussian-shaped electrical pulses of different amplitudes generated on the MCP's anode into common-shape pulses (e.g., pulses compatible with TTL/ESL logic circuitry) sent to TDC. Using CFD provides a time point correspondent to a position of peak maximum independent of variation in the peak amplitude caused by variation of the MCP or SEM gain.
Sources: en.wikipedia.org
SDMA, also known as 3,4-methylenethiooxy-N-methylamphetamine (3T-MDMA) or as MY100, is a putative entactogen of the phenethylamine and amphetamine families related to 3,4-methylenedioxy-N-methylamphetamine (MDMA). It is the analogue of MDMA in which the oxygen atom at the 3 position within the 3,4-methylenedioxy substitution has been replaced with a sulfur atom to give a 1,3-benzoxathiole rather than 1,3-benzodioxole ring system. The drug is also the N-methyl derivative of 3,4-methylenethiooxyamphetamine (SDA; 3T-MDA). SDMA is of interest for potential therapeutic use.
The pineal gland is located in the diencephalon of the brain. It primarily releases melatonin, which influences daily rhythms and may have an antigonadotropic effect in humans. It may also influence the melanotropes and melanocytes located in the skin.
==== Serbia ==== Taco Bell opened its first store in Serbia, in the capital city of Belgrade, on November 20, 2025, at the Ušće Shopping Center. Serbia is the second country of the former Yugoslavia in which Taco Bell is present. Second opened in Novi Sad.
=== Transmetallation === The transmetallation of the trans intermediate from the oxidative addition step is believed to proceed via a variety of mechanisms depending on the substrates and conditions. The most common type of transmetallation for the Stille coupling involves an associative mechanism. This pathway implies that the organostannane, normally a tin atom bonded to an allyl, alkenyl, or aryl group, can coordinate to the palladium via one of these double bonds. This produces a fleeting pentavalent, 18-electron species, which can then undergo ligand detachment to form a square planar complex again. Despite the organostannane being coordinated to the palladium through the R2 group, R2 must be formally transferred to the palladium (the R2-Sn bond must be broken), and the X group must leave with the tin, completing the transmetalation. This is believed to occur through two mechanisms. First, when the organostannane initially adds to the trans metal complex, the X group can coordinate to the tin, in addition to the palladium, producing a cyclic transition state. Breakdown of this adduct results in the loss of R3Sn-X and a trivalent palladium complex with R1 and R2 present in a cis relationship. Another commonly seen mechanism involves the same initial addition of the organostannane to the trans palladium complex as seen above; however, in this case, the X group does not coordinate to the tin, producing an open transition state. After the α-carbon relative to tin attacks the palladium, the tin complex will leave with a net positive charge.
Subfamily ABCC contains thirteen members and nine of these transporters are referred to as the Multidrug Resistance Proteins (MRPs). The MRP proteins are found throughout nature and they mediate many important functions. They are known to be involved in ion transport, toxin secretion, and signal transduction. Of the nine MRP proteins, four of them, MRP4, 5, 8, 9, (ABCC4, 5, 11, and 12), have a typical ABC structure with four domains, comprising two membrane spanning domains, with each spanning domain followed by a nucleotide binding domain. These are referred to as short MRPs. The remaining 5 MRP's (MRP1, 2, 6, 7) (ABCC1, 2, 3, 6 and 10) are known as long MRPs and feature an additional fifth domain at their N terminus. CFTR, the transporter involved in the disease cystic fibrosis, is also considered part of this subfamily. Cystic fibrosis occurs upon mutation and loss of function of CFTR. The sulfonylurea receptors (SUR), involved in insulin secretion, neuronal function, and muscle function, are also part of this family of proteins. Mutations in SUR proteins are a potential cause of Neonatal diabetes mellitus. SUR is also the binding site for drugs such as sulfonylureas and potassium-channel openers activators such as diazoxide.
Sources: en.wikipedia.org
Counter-Strike: Source was met with positive reviews from professional critics. Metacritic, a review aggregator website, awarded Source a rating of 88 out of a possible 100 based on 9 critic's reviews. IGN praised the game for its graphical improvements; Jeff Haynes said the game was "much more detailed, featuring many more polygons per model, bump mapping and other graphical enhancements" compared to the original.
The two studies where inconclusive for other outcome measures (including all-cause and cardiovascular mortality, non‐fatal myocardial infarction, non‐fatal stroke, congestive heart failure, serious and non‐serious adverse events (increased “non‐serious side effects” where concluded only for acarbose), hypoglycaemia, measures of blood glucose control, blood lipids, body weight, and blood pressure).
=== Background === After United States diplomatic cables leak, Russian Reporter magazine published the dispatches sent by then US Ambassador to Georgia John F. Tefft during the war from Tbilisi. The cables stated that the conflict was not the aim of Georgians, but they were drawn into it by South Ossetians. Some news agencies, such as Russian Rosbalt, reported that according to the leaked documents, Russia started the war in South Ossetia. However, the same cables were assessed differently by several Russian commentators, who said that this proved that the Georgians started the war. Russky Reporter was found to have possibly published hoax cables or misinterpretations. Director of the Georgian Security Analysis Center David J. Smith commented that the cables proved that Russia started the war.
The skin is the largest organ of the human body that restricts the movement of drug to the systemic circulation. The topical drug delivery system is a system where the drug reaches the systemic circulation through the protective skin layer. The main disadvantage of this route is the low diffusion rate of the drugs across the layer of skin which is the stratum corneum. To overcome this problem to a certain extent, ethosomes are used to enhance transdermal drug delivery systems.
Sources: en.wikipedia.org
No. It is a laboratory-made analog of growth hormone-releasing hormone. The natural hormone is a 44-residue peptide, while the analog is built on a shorter 29-residue fragment.
The original material included a linker that binds serum albumin. A later variant removed that linker to reduce the duration of action. Catalogs and papers did not consistently adopt separate names, so both remain widely labeled with the same term.
The amino acid sequence and the presence or absence of the linker group. Mass measured by spectrometry gives an independent check that separates the two forms.
Chromatography reports how much material elutes as a single peak but does not confirm what that material is. Mass spectrometry supplies the molecular mass, which is characteristic of a given sequence and its modifications. Together the two methods support both a purity figure and an identity claim.